Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Pilot Clinical Trial of Omega-3 Supplement vs. Placebo for Post Covid-19 Recovery Among Health Care Workers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Team member at Hackensack Meridian Health~* Age: 18+~* Willing to provide informed consent~* Formal diagnosis of COVID-19 via Polymerase Chain Reaction (PCR)test (if home test was done, team member must confirm via PCR test)~* Outpatient treatment only for covid-19; no hospitalization (most team members will be vaccinated and may likely have milder case)~* Must be experiencing 1+ ongoing covid-19 symptom being measured in this study (respiratory symptoms (shortness of breath, cough), fatigue, loss of taste, loss of smell)~* Symptom(s) have persisted for more than 12 weeks after initial infection~* Symptom(s) coincided with covid-19 infection and were not present prior to covid-19 infection~* Does not have soy allergy~* Does not have allergy to fish~* Able to participate in bi-weekly surveys in Research Electronic Data Capture (REDCap)~* Able to take own blood pressure and record it in bi-weekly REDCap survey~* Willing to participate in 12-week study and be assigned to either intervention or placebo arm~* Not currently taking an omega-3 supplement or other high-dose supplement (over 2,000 IU) with potential for aiding recovery of long covid syndrome (e.g. zinc, Vit C, Elderberry).~* Able to take/swallow six mini-pills daily~* Able and willing to give a spot blood sample (2 drops) at baseline and end of study.~Exclusion Criteria:~* Not a Team Member at Hackensack Meridian Health~* Not age 18+~* Unwilling to provide informed consent/ declined to take part~* No formal diagnosis of COVID-19 via PCR test (if home test was done, team member must confirm via PCR test)~* Were hospitalized for treatment of covid-19~* Not experiencing 1+ ongoing covid-19 symptom being measured in this study (respiratory symptoms (shortness of breath, cough), fatigue, loss of taste, loss of smell)~* Symptom(s) have persisted for more than 12 weeks after initial infection~* Symptom(s) did not coincide with covid-19 infection and were present prior to covid-19 infection~* Does have soy allergy~* Does have allergy to fish~* Not able to participate in bi-weekly surveys in REDCap~* Able to take own blood pressure and record it in bi-weekly REDCap survey~* Not willing to participate in 12-week study and be assigned to either intervention or placebo arm~* Currently taking an omega-3 supplement or other high-dose supplement (over 2,000 IU) with potential for aiding recovery of long covid syndrome (e.g. zinc, Vit C, Elderberry).~* Unable to take/swallow six mini-pills daily~* Not able and not willing to give a spot blood sample (2 drops) at baseline and end of study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: t

Study Arms:
- Study arm - Omega 3 supplement (Type: EXPERIMENTAL): Omega-3 (EPA+DHA) - Dose is 2,100mg per day via 3 mini-capsules, 2x/day (a total of 6 mini-capsules per day). Each capsule has 252mg of EPA and 102mg of DHA.
- Control arm - placebo (Type: PLACEBO_COMPARATOR): 3 Soybean Oil Placebo capsules 2x/day (a total of 6 mini-capsules per day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues